Literature DB >> 27915482

Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective study.

Susana Pinto1, Mamede de Carvalho1,2.   

Abstract

INTRODUCTION: Slow vital capacity (SVC) and forced vital capacity (FVC) are the most frequent used tests evaluating respiratory function in amyotrophic lateral sclerosis (ALS). No previous study has determined their interchangeability.
OBJECTIVE: To evaluate SVC-FVC correlation in ALS.
METHODS: Consecutive definite/probable ALS and primary lateral sclerosis (PLS) patients (2000-2014) in whom respiratory tests were performed at baseline/4-6months later were included. All were evaluated with revised ALS functional rating scale, the ALSFRS respiratory (R-subscore) and bulbar subscores, SVC, FVC, maximal inspiratory (MIP) and expiratory (MEP) pressures. SVC-FVC correlation was analysed by Pearson product-moment correlation test. Paired t-test compared baseline/follow-up values. Multilinear regression analysis modelled the relationship between tested variables.
RESULTS: We included 592 ALS (332 men, mean onset age 62.6 ± 11.8 years, mean disease duration 15.4 ± 15 months) and 19 PLS (11 men, median age 54 years, median disease duration 5.5 years) patients. SVC and FVC predicted values decreased 2.15%/month and 2.08%/month, respectively. FVC and SVC were strongly correlated. Both were strongly correlated with MIP and MEP and moderately correlated with R-subscore for the all population and spinal-onset patients, but weakly correlated for bulbar-onset patients.
CONCLUSIONS: FVC and SVC were strongly correlated and declined similarly. This correlation was preserved in bulbar-onset ALS and in spastic PLS patients.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; forced vital capacity; functional rating scale; maximal respiratory pressures; slow vital capacity

Mesh:

Year:  2016        PMID: 27915482     DOI: 10.1080/21678421.2016.1249486

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  9 in total

1.  Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Authors:  Jeffrey M Statland; Dan Moore; Yunxia Wang; Maureen Walsh; Tahseen Mozaffar; Lauren Elman; Sharon P Nations; Hiroshi Mitsumoto; J Americo Fernandes; David Saperstein; Ghazala Hayat; Laura Herbelin; Chafic Karam; Jonathan Katz; Heather M Wilkins; Abdulbaki Agbas; Russell H Swerdlow; Regina M Santella; Mazen M Dimachkie; Richard J Barohn
Journal:  Muscle Nerve       Date:  2018-11-26       Impact factor: 3.217

2.  Home-Based Music Therapy to Support Bulbar and Respiratory Functions of Persons with Early and Mid-Stage Amyotrophic Lateral Sclerosis-Protocol and Results from a Feasibility Study.

Authors:  Alisa T Apreleva Kolomeytseva; Lev Brylev; Marziye Eshghi; Zhanna Bottaeva; Jufen Zhang; Jörg C Fachner; Alexander J Street
Journal:  Brain Sci       Date:  2022-04-13

3.  Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].

Authors:  Benjamin Rix Brooks; Terry Heiman-Patterson; Martina Wiedau-Pazos; Shawn Liu; Jeffrey Zhang; Stephen Apple
Journal:  PLoS One       Date:  2022-06-14       Impact factor: 3.752

Review 4.  Diaphragmatic Neurophysiology and Respiratory Markers in ALS.

Authors:  Mamede de Carvalho; Michael Swash; Susana Pinto
Journal:  Front Neurol       Date:  2019-02-21       Impact factor: 4.003

5.  Using patient-reported symptoms of dyspnea for screening reduced respiratory function in patients with motor neuron diseases.

Authors:  Jochem Helleman; Esther T Kruitwagen-van Reenen; J Bakers; Willeke J Kruithof; Annerieke C van Groenestijn; Rineke J H Jaspers Focks; Arthur de Grund; Leonard H van den Berg; Johanna M A Visser-Meily; Anita Beelen
Journal:  J Neurol       Date:  2020-06-23       Impact factor: 4.849

6.  Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.

Authors:  Qi-Jie Zhang; Jian-Chai Huang; Jia Chen; Wei Hu; Liu-Qing Xu; Qi-Fu Guo
Journal:  BMC Neurol       Date:  2022-03-19       Impact factor: 2.474

7.  Comparison of Slow and Forced Vital Capacity on Ability to Evaluate Respiratory Function in Bulbar-Involved Amyotrophic Lateral Sclerosis.

Authors:  Xin Huang; Chenfang Du; Qiong Yang; Dongsheng Fan
Journal:  Front Neurol       Date:  2022-06-28       Impact factor: 4.086

Review 8.  Optimal NIV Medicare Access Promotion: Patients With Thoracic Restrictive Disorders: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society.

Authors:  Lisa F Wolfe; Joshua O Benditt; Loutfi Aboussouan; Dean R Hess; John M Coleman
Journal:  Chest       Date:  2021-07-30       Impact factor: 9.410

9.  Multiparametric Analysis of Sniff Nasal Inspiratory Pressure Test in Middle Stage Amyotrophic Lateral Sclerosis.

Authors:  Antonio Sarmento; Andrea Aliverti; Layana Marques; Francesca Pennati; Mario Emílio Dourado-Júnior; Guilherme Fregonezi; Vanessa Resqueti
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.